DXR Quote, Financials, Valuation and Earnings

Precision Optics Corp., Inc. has a net margin of -- compared to Daxor Corp.'s net margin of -24.5%. Daxor Corp.'s return on equity of 1.57% beat Precision Optics Corp., Inc.'s return on equity of -54.55%.

Daxor Corp. has a consensus price target of $22.50, signalling upside risk potential of 81.45%. On the other hand Precision Optics Corp., Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daxor Corp. has higher upside potential than Precision Optics Corp., Inc., analysts believe Daxor Corp. is more attractive than Precision Optics Corp., Inc..

Daxor Corp. has a beta of 0.011, which suggesting that the stock is 98.935% less volatile than S&P 500. In comparison Precision Optics Corp., Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics Corp., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Precision Optics Corp., Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Precision Optics Corp., Inc. quarterly revenues of $6.7M. Daxor Corp.'s net income of -- is lower than Precision Optics Corp., Inc.'s net income of -$1.6M. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Precision Optics Corp., Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 57.50x versus 1.58x for Precision Optics Corp., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Daxor Corp.'s net margin of -316.61%. Daxor Corp.'s return on equity of 1.57% beat Plus Therapeutics, Inc.'s return on equity of --.

Daxor Corp. has a consensus price target of $22.50, signalling upside risk potential of 81.45%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1898.55%. Given that Plus Therapeutics, Inc. has higher upside potential than Daxor Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Daxor Corp..

Daxor Corp. has a beta of 0.011, which suggesting that the stock is 98.935% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Daxor Corp.'s net income of -- is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 57.50x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech, Inc. has a net margin of -- compared to Daxor Corp.'s net margin of 3.17%. Daxor Corp.'s return on equity of 1.57% beat Sanara MedTech, Inc.'s return on equity of -20.48%.

Daxor Corp. has a consensus price target of $22.50, signalling upside risk potential of 81.45%. On the other hand Sanara MedTech, Inc. has an analysts' consensus of $40.00 which suggests that it could grow by 111.53%. Given that Sanara MedTech, Inc. has higher upside potential than Daxor Corp., analysts believe Sanara MedTech, Inc. is more attractive than Daxor Corp..

Daxor Corp. has a beta of 0.011, which suggesting that the stock is 98.935% less volatile than S&P 500. In comparison Sanara MedTech, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.90300000000001%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Sanara MedTech, Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Sanara MedTech, Inc. quarterly revenues of $26.3M. Daxor Corp.'s net income of -- is lower than Sanara MedTech, Inc.'s net income of $834.5K. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Sanara MedTech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 57.50x versus 1.59x for Sanara MedTech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Warby Parker, Inc. has a net margin of -- compared to Daxor Corp.'s net margin of 2.65%. Daxor Corp.'s return on equity of 1.57% beat Warby Parker, Inc.'s return on equity of 0.2%.

Daxor Corp. has a consensus price target of $22.50, signalling upside risk potential of 81.45%. On the other hand Warby Parker, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 21.33%. Given that Daxor Corp. has higher upside potential than Warby Parker, Inc., analysts believe Daxor Corp. is more attractive than Warby Parker, Inc..

Daxor Corp. has a beta of 0.011, which suggesting that the stock is 98.935% less volatile than S&P 500. In comparison Warby Parker, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Warby Parker, Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Warby Parker, Inc. quarterly revenues of $221.7M. Daxor Corp.'s net income of -- is lower than Warby Parker, Inc.'s net income of $5.9M. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Warby Parker, Inc.'s PE ratio is 5,910.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 57.50x versus 3.26x for Warby Parker, Inc.. Usually stocks with elevated PS ratios are considered overvalued.